How does Medi-Cal cover dermatology services in California?
Medi-Cal covers medically necessary dermatologic services through the county-organized managed care plan system. Coverage includes biopsy, excision, and Mohs surgery for skin cancer; evaluation and management for inflammatory dermatoses (eczema, psoriasis, acne with significant scarring or symptoms); destruction of precancerous lesions (17000, 17003); and limited biologic medications for severe psoriasis or hidradenitis suppurativa through Drug Medi-Cal Rx (administered by Magellan Medicaid Administration). Cosmetic procedures are not covered. Each Medi-Cal Managed Care Plan — L.A. Care, Health Net, Molina, CalOptima, Inland Empire Health Plan, Partnership HealthPlan, Anthem Medi-Cal — has its own dermatology network, prior auth requirements, and fee schedule. We maintain per-MCP workflows so authorization, claim submission, and follow-up don't run aground on plan-specific rules.
What documentation does Anthem Blue Cross require for Mohs surgery in California?
Anthem Blue Cross requires Mohs micrographic surgery documentation referenced to the American Academy of Dermatology Mohs Appropriate Use Criteria (AUC). The AUC scoring grid evaluates tumor location (high-risk areas: face, ears, hands, feet, genitalia, periauricular), histology (recurrent, aggressive subtypes like morpheaform/infiltrative basal cell or perineural squamous cell), patient factors (immunosuppression, recurrent disease, prior radiation), and tumor characteristics (size, depth, defined borders). Mohs is appropriate when the lesion scores in the 'appropriate' tier per AUC. We submit Mohs auth and post-procedure documentation with: lesion location with anatomic specificity, biopsy histology including subtype and growth pattern, AUC tier justification, and tumor stage rationale. Repair codes (12001-13160, 14000-14302, 15000-15278) are billed separately with appropriate modifiers and place-of-service codes.
How does the prompt-pay rule affect California dermatology cash flow?
California Health & Safety Code 1371.35 requires plans to pay clean electronic claims within 30 working days and paper claims within 45 working days. 'Working days' excludes weekends and California state holidays. Default triggers 15% annual interest plus a $10 per-claim penalty, recoverable by the provider. For dermatology practices, cash flow impact concentrates on Mohs claims ($1,500-$3,000 per session including repair) where stalled balances accrue meaningful interest, and on high-volume biopsy/destruction billing where the per-claim count multiplies the $10 penalty. We track every clean claim against the working-day clock, flag stalled payments at day 25, and escalate to DMHC (Knox-Keene plans) or CDI (non-Knox-Keene) when payers default. Recovering the interest is real, but the operational benefit is faster average days-in-AR through pattern enforcement.
What's the prior auth process for biologics in California dermatology?
Biologics for dermatology indications (Humira, Stelara, Cosentyx, Skyrizi, Dupixent, Tremfya, others) require prior authorization across virtually all California payers. The process varies by plan — Anthem Blue Cross typically routes through Carelon or MagellanRx; Blue Shield uses CVS Caremark or delegated PBMs depending on the product line; Medi-Cal Drug Medi-Cal Rx uses Magellan Medicaid Administration. Step therapy is the norm: for psoriasis, documented failed trial of methotrexate, cyclosporine, or phototherapy is typically required before biologic approval; for atopic dermatitis (Dupixent), failed topical and systemic alternatives. We submit auth packets with diagnosis severity (PASI/EASI score where applicable), prior treatment timeline with dates and outcomes, contraindications to step-therapy alternatives, and treatment goals. Adverse determinations can be peer-to-peer appealed and escalated to DMHC Independent Medical Review for Knox-Keene plans.
Does AB 72 affect out-of-network dermatology billing in California?
Yes. California AB 72 (effective 2017) protects patients from surprise medical bills for non-emergency out-of-network services delivered at in-network facilities, predating the federal No Surprises Act (NSA, effective 2022). The two regimes interact: ERISA self-funded plans fall under the NSA with the federal IDR process; California-regulated plans fall under AB 72 with the state's independent dispute resolution. For dermatology, the protection applies when an in-network facility (hospital, ambulatory surgery center) uses an out-of-network dermatologist for a non-emergency service the patient didn't elect. We bill out-of-network services at the AB 72 benchmark or NSA qualifying payment amount as appropriate, file IDR requests when offered reimbursement is below median in-network rate, and document the medical necessity narrative each process requires. Routine in-office dermatology where the patient chose an out-of-network provider falls outside AB 72 protection.
What's the audit risk on 17003 utilization in California?
17003 (destruction of premalignant lesion, each additional lesion 2-14) carries documented utilization edit risk in California. Anthem Blue Cross, Blue Shield of California, and several Medi-Cal MCPs flag claims with high 17003 counts in a single encounter — the historical pattern of billing 14 actinic keratosis destructions on a single visit triggers automated review. The medical necessity standard requires documentation of each lesion: anatomic location, clinical appearance, and rationale for destruction (versus observation or topical treatment). California's high actinic keratosis prevalence (climate-driven) genuinely supports higher-than-national-average utilization, but we document each lesion individually and avoid the routine 'destroy 14, bill the max' pattern that triggers audit. For high-count days, we document the clinical picture and treatment plan rationale to support the volume.